A 67-year-old man with Stage IIIA non-small cell lung cancer (NSCLC) and ECOG performance status 1 has a PD-L1 expression of 85%. He has no driver mutations (EGFR/ALK negative). Which treatment approach is MOST appropriate?
-
A
Cisplatin/pemetrexed chemotherapy alone
-
B
Pembrolizumab monotherapy
-
C
Concurrent chemoradiation followed by durvalumab
-
D
EGFR-targeted therapy with osimertinib